首页> 外文期刊>Brachytherapy >Regulatory evaluation of prostate volume implants: Pitfalls of a retrospective assessment
【24h】

Regulatory evaluation of prostate volume implants: Pitfalls of a retrospective assessment

机译:前列腺体积植入物的法规评估:回顾性评估的误区

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Evaluate for regulatory compliance the prostate implants from the Philadelphia Veterans Medical Center applying both an activity-based and volume-corrected D 90 (the maximum dose delivered to 90% of the prostate volume) metrics. Methods and Materials: Dosimetry from 107 prostate implants performed at the Philadelphia Veterans Medical Center used immediate postprocedural CT image sets. D 90 values were adjusted for volume differences from planning volumes. Medical events (MEs) determined from the volume-corrected data were compared with an activity-based metric. Results: Examination of images using original and third-party reviewed prostate contours revealed 56 and 62 cases with D 90 values 80% of the prescription dose, respectively. Because postprocedural prostate volumes were on average 55.7% larger than the planned volume, clinical nomogram-based doses using the implanted activity and actual volumes found 34-47 implants failing to achieve doses greater than 80% of the prescription dose.Volume correction identified 20 MEs, 9 cases with D 90 values within 4% of the ME threshold and 11 significantly inferior cases with median D 90 values 52% of the prescribed dose.Eleven implants also had 20% or more seeds beyond the treatment site according to an activity metric recommended by the VHA Blue Ribbon Panel. Ten of these 11 cases were also identified by volume-corrected D 90 metric. The remaining 96 cases, however, had 95% (±6%) of seeds placed within the treatment site. Conclusions: Of the cases reported to the United States Nuclear Regulatory Commission (NRC) on the basis of Day-1 D 90 values, many appear to have been acceptable implants relative to standard-of-practice clinical criteria. The activity-based dose metric, endorsed by the NRC Advisory Committee on the Medical Uses of Isotopes in 2005 and recommended by the VHA Blue Ribbon Panel for Prostate Brachytherapy yields a more robust determination of ME for this population of implants.
机译:目的:评估费城退伍军人医疗中心的前列腺植入物是否符合法规要求,同时采用基于活动和体积校正的D 90(最大剂量达到前列腺体积的90%)。方法和材料:在费城退伍军人医疗中心对107例前列腺植入物进行剂量测定,使用了即时的术后CT图像集。 D 90值已针对与计划产量的差异进行了调整。将根据体积校正数据确定的医疗事件(ME)与基于活动的指标进行比较。结果:使用原始和第三方检查的前列腺轮廓检查图像时,分别有56例和62例D 90值小于处方剂量的80%。由于手术后前列腺体积平均比计划体积大55.7%,因此使用植入活动和实际体积的基于临床列线图的剂量发现34-47个植入物无法达到大于处方剂量的80%的体积校正确定了20个ME ,其中9例D 90值在ME阈值4%以内,11例中度D 90值<处方剂量的52%的严重劣等病例。根据活性指标,11个植入物在治疗部位以外还具有20%或更多的种子由VHA蓝带面板推荐。在这11例病例中,有10例也通过体积校正D 90指标确定。但是,其余96例病例中有95%(±6%)的种子置于治疗部位。结论:在根据Day-1 D 90值向美国核监管委员会(NRC)报告的病例中,相对于实践标准临床标准,许多病例似乎是可以接受的。 2005年,NRC同位素医学用途咨询委员会认可并由VHA前列腺癌近距离放射治疗蓝带专家组推荐的基于活动的剂量标准可更可靠地确定该植入物人群的ME。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号